[go: up one dir, main page]

DE69929310D1 - Tumorassoziierte antigenderivate der mage-familie, nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung - Google Patents

Tumorassoziierte antigenderivate der mage-familie, nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung

Info

Publication number
DE69929310D1
DE69929310D1 DE69929310T DE69929310T DE69929310D1 DE 69929310 D1 DE69929310 D1 DE 69929310D1 DE 69929310 T DE69929310 T DE 69929310T DE 69929310 T DE69929310 T DE 69929310T DE 69929310 D1 DE69929310 D1 DE 69929310D1
Authority
DE
Germany
Prior art keywords
vaccination
compositions
code
preparation
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69929310T
Other languages
English (en)
Other versions
DE69929310T2 (de
Inventor
Silva Teresa Cabezon
Joseph Cohen
Moncef Slaoui
Bassols Carlota Vinals
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9802543.0A external-priority patent/GB9802543D0/en
Priority claimed from GBGB9802650.3A external-priority patent/GB9802650D0/en
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Application granted granted Critical
Publication of DE69929310D1 publication Critical patent/DE69929310D1/de
Publication of DE69929310T2 publication Critical patent/DE69929310T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE69929310T 1998-02-05 1999-02-02 Tumorassoziierte antigenderivate der mage-familie, nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung Expired - Lifetime DE69929310T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9802543.0A GB9802543D0 (en) 1998-02-05 1998-02-05 Vaccine
GB9802543 1998-02-05
GB9802650 1998-02-06
GBGB9802650.3A GB9802650D0 (en) 1998-02-06 1998-02-06 Vaccine
PCT/EP1999/000660 WO1999040188A2 (en) 1998-02-05 1999-02-02 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccinations

Publications (2)

Publication Number Publication Date
DE69929310D1 true DE69929310D1 (de) 2006-03-30
DE69929310T2 DE69929310T2 (de) 2006-08-03

Family

ID=26313069

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69942214T Expired - Lifetime DE69942214D1 (de) 1998-02-05 1999-02-02 Verfahren zur Reinigung oder Herstellung der MAGE Protein
DE69929310T Expired - Lifetime DE69929310T2 (de) 1998-02-05 1999-02-02 Tumorassoziierte antigenderivate der mage-familie, nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
DE69943359T Expired - Lifetime DE69943359D1 (de) 1998-02-05 1999-02-02 Tumorassoziierte Antigenderivate der Mage-Familie, zur Herstellung von Fusionsproteinen mit T-Helper Epitope und Zusammensetzungen zur Impfung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69942214T Expired - Lifetime DE69942214D1 (de) 1998-02-05 1999-02-02 Verfahren zur Reinigung oder Herstellung der MAGE Protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69943359T Expired - Lifetime DE69943359D1 (de) 1998-02-05 1999-02-02 Tumorassoziierte Antigenderivate der Mage-Familie, zur Herstellung von Fusionsproteinen mit T-Helper Epitope und Zusammensetzungen zur Impfung

Country Status (25)

Country Link
US (3) US8097257B2 (de)
EP (4) EP1659179B1 (de)
JP (2) JP4768121B2 (de)
KR (2) KR100633212B1 (de)
CN (1) CN1227360C (de)
AR (1) AR018064A1 (de)
AT (4) ATE505542T1 (de)
AU (1) AU737337B2 (de)
BR (1) BR9907691B1 (de)
CA (2) CA2584482C (de)
CY (4) CY1105685T1 (de)
CZ (2) CZ298364B6 (de)
DE (3) DE69942214D1 (de)
DK (4) DK1584685T3 (de)
ES (2) ES2255248T3 (de)
HU (1) HU228467B1 (de)
IL (4) IL137442A0 (de)
NO (2) NO328507B1 (de)
NZ (1) NZ506086A (de)
PT (4) PT1053325E (de)
SA (1) SA99200126B1 (de)
SI (4) SI1659179T1 (de)
TR (1) TR200002284T2 (de)
TW (1) TWI238853B (de)
WO (1) WO1999040188A2 (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE505542T1 (de) 1998-02-05 2011-04-15 Glaxosmithkline Biolog Sa Tumorassoziierte antigenderivate der mage-familie,zur herstellung von fusionsproteinen mit t-helper epitope und zusammensetzungen zur impfung
CZ20011049A3 (cs) 1998-10-05 2002-08-14 Pharmexa A/S Imunogenní kompozice a způsob selekce imunogenního analogu
DK1117421T3 (da) * 1998-10-05 2004-11-01 Pharmexa As Hidtil ukendte fremgangsmåder til terapuetisk vaccination
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
AU5615601A (en) * 2000-02-23 2001-09-03 Smithkline Beecham Biolog Novel compounds
EP1385541B1 (de) * 2000-04-13 2008-06-18 Corixa Corporation Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten
PT1282702E (pt) 2000-05-10 2007-02-28 Ludwig Inst Cancer Res Polipéptidos imunogénicos codificados por minigenes mage e suas utilizações
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
DK2230253T3 (da) * 2000-06-05 2013-11-18 Brigham & Womens Hospital Antistoffer mod en homolog til MDR-P-glycoproteinet på kromosom 7p15-21 og anvendelser deraf
WO2001098460A2 (en) 2000-06-20 2001-12-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
CN100548373C (zh) * 2000-10-18 2009-10-14 葛兰素史密丝克莱恩生物有限公司 疫苗
DE60131670T2 (de) * 2000-10-18 2008-10-30 Glaxosmithkline Biologicals S.A. Impfstoffe gegen Krebskrankheiten
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
AU2002364161A1 (en) 2001-12-12 2003-06-23 Aventis Pasteur Limited Enhancement of the immune response using cd36-binding domain
DE602004031681D1 (de) 2003-07-21 2011-04-14 Transgene Sa Multifunktionelle Cytokine
CA2537140A1 (en) * 2003-08-29 2005-03-10 The Nottingham Trent University Gastric and prostate cancer associated antigens
CA2537900A1 (en) * 2003-09-03 2005-04-28 Dendritherapeutics, Inc. Multiplex vaccines
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
EP2386314A1 (de) 2005-03-31 2011-11-16 GlaxoSmithKline Biologicals SA Impfstoff gegen Chlamydieninfektion
ES2524572T3 (es) 2005-04-29 2014-12-10 Glaxosmithkline Biologicals S.A. Procedimiento novedoso de prevención o tratamiento de infección por M. tuberculosis
NZ563708A (en) * 2005-05-26 2010-08-27 Cytos Biotechnology Ag Scalable fermentation process
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20090028888A1 (en) * 2005-11-14 2009-01-29 Alain Bergeron Cancer Antigen Mage-A9 and Uses Thereof
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
JP5170976B2 (ja) * 2006-04-11 2013-03-27 株式会社イミュノフロンティア タンパク質複合体およびその製造方法
PE20080742A1 (es) 2006-06-02 2008-08-06 Glaxosmithkline Biolog Sa Perfil genico y procedimiento de identificacion
GB0612342D0 (en) * 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
ES2387327T5 (es) 2006-09-26 2024-11-19 Access To Advanced Health Inst Composición de vacuna que contiene un adyuvante sintético
GB0700284D0 (en) * 2007-01-08 2007-02-14 Glaxosmithkline Biolog Sa Combination therapy
CA2674552A1 (en) * 2007-01-15 2008-07-24 Glaxosmithkline Biologicals S.A. Vaccine
RU2010114017A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Терапевтическое применение натрийуретического пептида в-типа и гормона роста человека 1-43
WO2009033780A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of growth hormone-releasing factor and/or k237 as a therapeutic agents
NZ596545A (en) * 2007-09-17 2013-05-31 Glaxosmithkline Biolog Sa Improved detection of mage-a expression
ATE553774T1 (de) * 2007-10-19 2012-05-15 Novartis Ag Meningokokkenimpfstoffformulierungen
EP2408933A2 (de) 2009-03-17 2012-01-25 MDxHealth SA Verbesserter genexpressionsnachweis
JP2012528106A (ja) 2009-05-27 2012-11-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｃａｓｂ７４３９構築物
TWI549688B (zh) 2009-06-05 2016-09-21 美國疾病傳染研究機構 合成的葡萄吡喃糖基脂質佐劑
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
KR20120129927A (ko) 2010-01-27 2012-11-28 글락소 그룹 리미티드 변형된 투베르쿨로시스 항원
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
EP2675473A1 (de) 2011-02-15 2013-12-25 Immune Design Corp. Verfahren zur verbesserung von immunogenspezifischen immunreaktionen durch vektorisierte impfstoffe
BRPI1100857A2 (pt) * 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
BR112013025799A2 (pt) 2011-04-08 2016-12-20 Immune Design Corp método para induzir uma resposta imune em um sujeito, e, preparação
CN102251034B (zh) * 2011-07-05 2012-11-21 北京大学人民医院 基于mage-c2/ct10基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒
HUE042327T2 (hu) 2011-08-30 2019-06-28 Astex Pharmaceuticals Inc Decitabin-származék készítmények
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
CN104066445A (zh) * 2011-12-22 2014-09-24 葛兰素史克有限责任公司 用mage-a3免疫治疗剂与braf抑制剂和/或mek抑制剂治疗癌症的方法
PT2811981T (pt) 2012-02-07 2019-06-12 Infectious Disease Res Inst Formulações adjuvantes melhoradas que compreendem os agonistas de tlr4 e os seus métodos de utilização
ES2673556T3 (es) 2012-05-16 2018-06-22 Immune Design Corp. Vacunas para el VHS-2
US9657076B2 (en) 2012-10-23 2017-05-23 Emory University GM-CSF and IL-4 conjugates, compositions, and methods related thereto
LT2961388T (lt) 2013-03-01 2019-08-26 Astex Pharmaceuticals, Inc. Vaistų deriniai
BR112015025709A2 (pt) 2013-04-18 2017-07-18 Immune Design Corp monoterapia com gla para uso em tratamento de câncer
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
EP3915579A1 (de) 2013-12-31 2021-12-01 Infectious Disease Research Institute Impfstoffformulierungen mit einzelphiole
EP3104878B1 (de) 2014-02-14 2019-05-22 Immune Design Corp. Immuntherapie von krebs durch kombination von lokaler und systemischer immunstimulation
US20170196954A1 (en) 2014-07-15 2017-07-13 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
CA2991167A1 (en) 2015-07-02 2017-01-05 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
CN105181966B (zh) * 2015-09-02 2017-08-11 南通大学附属医院 一种mage‑a9的用途
KR102566134B1 (ko) 2015-12-07 2023-08-10 삼성전자주식회사 반도체 소자의 3d 프로파일링 시스템 및 이의 동작 방법
WO2017176076A1 (en) 2016-04-06 2017-10-12 Ewha University - Industry Collaboration Foundation A peptide with ability to penetrate cell membrane
CN109312402A (zh) 2016-04-11 2019-02-05 得克萨斯州大学系统董事会 用于检测单个t细胞受体亲和力和序列的方法和组合物
IL314130A (en) 2016-05-16 2024-09-01 Access To Advanced Health Inst Formulation containing tlr agonist and methods of use
BR112018073676B1 (pt) 2016-05-16 2023-10-03 University Of Virginia Patent Foundation Lipossomas peguilados e métodos de uso
MX393217B (es) 2016-06-01 2025-03-11 Infectious Disease Res Inst Particulas de nanoalumbre que contienen un agente de dimensionamiento
KR102673794B1 (ko) 2017-06-15 2024-06-11 액세스 투 어드밴스드 헬스 인스티튜트 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
WO2019025863A2 (en) 2017-08-03 2019-02-07 Otsuka Pharmaceutical Co., Ltd. MEDICAMENT COMPOUND AND METHODS OF PURIFICATION
AU2018330165B2 (en) 2017-09-08 2025-07-17 Access To Advanced Health Institute Liposomal formulations comprising saponin and methods of use
EP3883955A1 (de) 2018-11-19 2021-09-29 Board of Regents, The University of Texas System Modularer, polycistronischer vektor für car- und tcr-transduktion
KR20210096638A (ko) 2018-11-28 2021-08-05 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 억제성 환경에 대한 기능 및 내성을 증진시키기 위한 면역 세포의 멀티플렉스 게놈 편집
CA3121210A1 (en) 2018-11-29 2020-06-04 Board Of Regents, The University Of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
BR112021023726A2 (pt) 2019-05-25 2022-02-15 Infectious Disease Res Inst Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
US20230106973A1 (en) 2020-02-17 2023-04-06 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
AU2021335334A1 (en) 2020-09-04 2023-04-20 Access To Advanced Health Institute Genetically-adjuvanted rna vaccines
CA3174411A1 (en) 2020-09-04 2022-03-10 Ryan M. Kramer Co-lyophilized rna and nanostructured lipid carrier
WO2022104109A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
AU2021388155A1 (en) 2020-11-25 2023-06-15 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
AU2021406131A1 (en) 2020-12-23 2023-08-03 Access To Advanced Health Institute Solanesol vaccine adjuvants and methods of preparing same
EP4169513A1 (de) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Hilfsstoffzusammensetzung enthaltend sting agonisten
EP4436595A1 (de) 2021-11-22 2024-10-02 Pfizer Inc. Verringerung des risikos von antigen-mimetika in immunogenen arzneimitteln
WO2023211972A1 (en) 2022-04-28 2023-11-02 Medical University Of South Carolina Chimeric antigen receptor modified regulatory t cells for treating cancer
AU2023336224A1 (en) 2022-09-09 2025-03-27 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4302386A (en) 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
US4384995A (en) 1980-01-16 1983-05-24 The Ohio State University Antigenic modification of polypeptides
US4526716A (en) 1981-11-20 1985-07-02 The Ohio State University Antigenic modification of polypeptides
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
AR241713A1 (es) 1984-08-30 1992-11-30 Smithkline Beckman Corp Molecula de dna con una secuencia de bases que codifica la proteina c13 y preparacion de vacunas contra la gripe.
ZA896627B (en) * 1988-08-31 1991-03-27 Smithkline Beecham Corp Vaccinal polypeptides
GB8824496D0 (en) 1988-10-19 1988-11-23 Beecham Group Plc Process
US6780407B1 (en) 1989-03-08 2004-08-24 Aventis Pasteur Pox virus comprising DNA sequences encoding CEA and B7 antigen
CA2022752C (en) * 1989-08-11 1998-07-07 Naomi Kitamura Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
AU8294991A (en) 1990-07-23 1992-02-18 Zymogenetics Inc. Protease resistant pdgf and methods of use
US5925729A (en) 1991-05-23 1999-07-20 Ludwig Institute For Cancer Research Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5541104A (en) 1991-05-23 1996-07-30 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
DE69231666T2 (de) * 1991-11-14 2001-05-10 Brigham And Women's Hospital, Boston Die nitrosylierung von enzym-sh gruppen als eine therapeutische massnahme
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
GB9213559D0 (en) 1992-06-25 1992-08-12 Smithkline Beecham Biolog Vaccines
DE69333670T2 (de) 1992-08-31 2005-03-10 Ludwig Institute For Cancer Research Vom mage-3-gen abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen
NZ271774A (en) * 1993-08-06 1998-02-26 Cytel Corp Immunogenic peptides from the c-terminus of the mage-1 (melanoma) antigen
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JPH09509832A (ja) 1994-03-01 1997-10-07 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ Ｍａｇｅ−３遺伝子発現による癌状態の判定
US5879687A (en) * 1994-04-22 1999-03-09 Corixa Corporation Methods for enhancement of protective immune responses
ATE328890T1 (de) 1994-07-15 2006-06-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
EP0782453A1 (de) * 1994-09-30 1997-07-09 Ludwig Institute For Cancer Research Zusammensetzungen, welche tumor abstossende antigen-vorläufer oder tumor abstossende antigene enthalten und ein adjuvants und/oder wachstumsfaktoren
US5612030A (en) * 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US6017705A (en) 1995-03-14 2000-01-25 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-B family and uses thereof
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP0873350A4 (de) 1995-06-29 1999-06-30 Ludwig Inst Cancer Res Isolierte nukleinsäuremoleküle, die den maustumoralstossungs-antigenvorläufer smage-3 kodieren
AU7440196A (en) 1995-10-12 1997-04-30 Chiron Corporation Baboon mage-3 homologs, dna encoding the homologs, and a process for their use
US6265215B1 (en) 1996-09-13 2001-07-24 Ludwig Institute For Cancer Research Isolated peptides which complex with HLA-Cw16 and uses thereof
US5908778A (en) 1996-10-03 1999-06-01 Ludwig Institute For Cancer Research Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof
CA2218456A1 (en) 1996-10-15 1998-04-15 The Rockefeller University Purified stat proteins and methods of purifying thereof
EP0941366A2 (de) 1996-11-06 1999-09-15 Whitehead Institute For Biomedical Research Biallelische marker
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
US6340461B1 (en) 1996-12-17 2002-01-22 David Stephen Terman Superantigen based methods and compositions for treatment of diseases
US6287569B1 (en) 1997-04-10 2001-09-11 The Regents Of The University Of California Vaccines with enhanced intracellular processing
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US6027924A (en) 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
US20020176865A1 (en) 1997-04-25 2002-11-28 Sophie Lucas Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B families and uses thereof
US6043084A (en) 1997-10-10 2000-03-28 Ludwig Institute For Cancer Research Isolated nucleic acid molecules associated with colon cancer and methods for diagnosing and treating colon cancer
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
US5965535A (en) 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6291430B1 (en) * 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
ATE505542T1 (de) 1998-02-05 2011-04-15 Glaxosmithkline Biolog Sa Tumorassoziierte antigenderivate der mage-familie,zur herstellung von fusionsproteinen mit t-helper epitope und zusammensetzungen zur impfung
WO1999053095A2 (en) 1998-04-09 1999-10-21 Whitehead Institute For Biomedical Research Biallelic markers
US6686147B1 (en) 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor

Also Published As

Publication number Publication date
ATE513042T1 (de) 2011-07-15
JP4768121B2 (ja) 2011-09-07
EP1659178A2 (de) 2006-05-24
PT1659179E (pt) 2011-09-16
EP1584685A3 (de) 2005-12-07
EP1659179B1 (de) 2011-06-15
KR100824105B1 (ko) 2008-04-21
EP1659178A3 (de) 2007-01-17
NZ506086A (en) 2003-01-31
CN1295616A (zh) 2001-05-16
WO1999040188A3 (en) 1999-10-14
EP1053325B1 (de) 2006-01-04
NO20003958D0 (no) 2000-08-04
EP1659179A2 (de) 2006-05-24
NO331719B1 (no) 2012-03-05
TWI238853B (en) 2005-09-01
EP1053325A2 (de) 2000-11-22
DE69929310T2 (de) 2006-08-03
DE69943359D1 (de) 2011-05-26
WO1999040188A2 (en) 1999-08-12
US8097257B2 (en) 2012-01-17
IL188875A0 (en) 2009-02-11
US20120269835A1 (en) 2012-10-25
US20100204458A1 (en) 2010-08-12
CY1111672T1 (el) 2015-10-07
DK1659179T3 (da) 2011-10-10
DE69942214D1 (de) 2010-05-12
HK1093522A1 (en) 2007-03-02
CA2319309A1 (en) 1999-08-12
JP2002502604A (ja) 2002-01-29
EP1659179A3 (de) 2007-01-17
CY1111831T1 (el) 2015-10-07
DK1659178T3 (da) 2010-07-12
IL179010A0 (en) 2007-03-08
SI1053325T1 (sl) 2006-06-30
US8597656B2 (en) 2013-12-03
NO20003958L (no) 2000-10-04
KR20010040675A (ko) 2001-05-15
CZ20002869A3 (cs) 2001-01-17
PT1659178E (pt) 2010-06-28
DK1584685T3 (da) 2011-07-11
SI1659178T1 (sl) 2010-07-30
CY1110180T1 (el) 2015-01-14
HU228467B1 (en) 2013-03-28
HUP0102639A1 (hu) 2001-11-28
EP1584685B1 (de) 2011-04-13
US8044183B2 (en) 2011-10-25
BR9907691B1 (pt) 2011-05-31
HK1033838A1 (en) 2001-09-28
NO20091665L (no) 2000-10-04
HUP0102639A3 (en) 2004-04-28
DK1053325T3 (da) 2006-05-22
SA99200126B1 (ar) 2006-08-20
HK1083026A1 (en) 2006-06-23
CA2584482C (en) 2012-03-27
TR200002284T2 (tr) 2000-11-21
PL342852A1 (en) 2001-07-16
CN1227360C (zh) 2005-11-16
PT1584685E (pt) 2011-06-17
ATE505542T1 (de) 2011-04-15
ATE462788T1 (de) 2010-04-15
SI1584685T1 (sl) 2011-07-29
PT1053325E (pt) 2006-05-31
CZ298347B6 (cs) 2007-09-05
HK1093521A1 (en) 2007-03-02
NO328507B1 (no) 2010-03-08
IL137442A0 (en) 2001-07-24
JP2009201510A (ja) 2009-09-10
CY1105685T1 (el) 2010-12-22
KR100633212B1 (ko) 2006-10-11
EP1659178B1 (de) 2010-03-31
CA2319309C (en) 2010-08-10
SI1659179T1 (sl) 2011-10-28
IL188875A (en) 2011-08-31
ES2342416T3 (es) 2010-07-06
AU737337B2 (en) 2001-08-16
BR9907691A (pt) 2000-11-14
CZ298364B6 (cs) 2007-09-05
AU2722099A (en) 1999-08-23
KR20060067977A (ko) 2006-06-20
EP1584685A2 (de) 2005-10-12
AR018064A1 (es) 2001-10-31
ATE315088T1 (de) 2006-02-15
CA2584482A1 (en) 1999-08-12
ES2255248T3 (es) 2006-06-16
US20100209444A1 (en) 2010-08-19
IL137442A (en) 2008-04-13

Similar Documents

Publication Publication Date Title
DE69929310D1 (de) Tumorassoziierte antigenderivate der mage-familie, nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
DE69834437D1 (de) Verfahren zur Herstellung von Fenofibrathaltigen Arzneizusammensetzungen mit erhöhter Bioverfügbarkeit
DE50303749D1 (de) Verfahren zur herstellung von phthalocyaninpigmentzubereitungen
AU6160201A (en) Human polypeptides causing or leading to the killing of cells including lymphoidtumor cells
DE60010285D1 (de) Verfahren zur Herstellung von Amino-Oxide
DE69923906D1 (de) Verfahren zur Herstellung von Pyrazolo-(4,3-d)pyrimidin-7-ones und Zwischenprodukte davon
DE59702308D1 (de) Verfahren zur Herstellung salzarmer Präparationen von Kondensationsprodukten
WO2001032882A3 (en) Nucleic acids and proteins from group b streptococcus
DE69923801D1 (de) Verfahren zur Herstellung von Aldehyden
DE60239842D1 (de) Verfahren zur Herstellung von 10,11-dihydro-10-oxo-5h-dibenzoÄb,fÜazepin-5-carboxamid
DE60200099D1 (de) Verfahren zur Herstellung von Isobutylenpolymeren
DE69810531D1 (de) Verfahren zur Herstellung von Naphtalin-2,6-dicarbonsäure
WO1999058639A3 (en) Structural proteins of fish pancreatic disease virus and uses thereof
DE69804572D1 (de) Verfahren zur Herstellung von Bisphenol-A
DE60228444D1 (de) Verfahren zur herstellung von cumylphenol
DE59802620D1 (de) Verfahren zur Herstellung von trans-(R,R)-Actinol
DE60108105D1 (de) Verfahren zur Herstellung von 5-substituierten Isobenzofuranen
DE60032308T8 (de) Verfahren zur Herstellung von Trichloressigsäure
DE69830156D1 (de) Zusammensetzungen zur immunverstärkung von impfstoffen
DE60230097D1 (de) Verfahren zur herstellung von 1,5-diaminonaphthalinen
DE60026123D1 (de) Verfahren zur Herstellung von hitzevulkanisierbaren Silikonzusammensetzungen
DE69910155D1 (de) Verfahren zur Herstellung von Isobutylenglycol
DE50015611D1 (de) Verfahren zur Herstellung von 2,3-Pyridindicarbonsäuren
DE60143350D1 (de) Verfahren zur herstellung von 1,3-dialkyl-2-imidazolidinon-derivaten
DE69802312D1 (de) Verfahren zur Herstellung von 3,3',5,5'-Tetra-b-Butylbiphenol

Legal Events

Date Code Title Description
8364 No opposition during term of opposition